Proactive Investors - Run By Investors For Investors

Bristol-Myers Squibb’s new dosing for cancer drug Opdivo gets FDA green light

The approval is for a supplemental Biologics Licence Application which updates the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks
cancer
Johanna Mercier, head, U.S. Commercial, Bristol-Myers said: “With this approval, we now offer the most robust range of dosing options for an Immuno-Oncology medicine, providing enhanced flexibility to help address each patient’s specific needs.”

Bristol-Myers Squibb Co (NYSE:BMY) said the US Food and Drug Administration (FDA) has given the green light for a new dosing schedule for its drug Opdivo, for a number of cancers that it is already approved for.

The approval is for a supplemental Biologics Licence Application (sBLA) which updates the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks.

READ: Bristol-Myers shares on the uptick after positive lung cancer trial results and market beating fourth quarter results

Opdivo is already approved for every two weeks at 240 mg and for a shorter 30-minute infusion across all approved indications.

The company said in a statement that the dosing schedule updates for an additional approved indication may be submitted to the FDA in the future.

Jeffrey S Weber, the deputy director of the Perlmutter Cancer Center at NYU Langone Health: “… some patients may need the support of two-week visits with their health care team, while for others, a four-week interval may be more appropriate and better suited to their treatment needs. With this approval, we now have additional ways to help tailor patient care.”

View full BMY profile View Profile

Bristol-Myers Squibb Co Timeline

Related Articles

researcher
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
Pictured is the company's myLotus test
Wed
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
man pointing to brain
April 25 2019
Brain Scientific’s EEG technology is far cheaper and less bulky than a traditional EEG system, but provides EEG tracings of the same quality
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use